Literature DB >> 3280813

Update in cancer chemotherapy: genitourinary tract cancer, Part 3: Cancer of the prostate.

J C Wright.   

Abstract

An update of the state of the art of cancer chemotherapeutic treatment of genitourinary tract cancer is described in this multi-part series: included are cancers of the kidney, bladder, prostate, testicle, ovary, uterus, vulva, and gestational trophoblastic neoplasms. Part 3 is a review of treatments for cancer of the prostate.The role of cancer chemotherapeutics as adjuvant therapy and in combination modalities in the treatment of prostatic carcinoma has yet to be determined. No single agent or combination can be considered standard therapy. The role of chemotherapy in prostatic carcinoma needs further definition. Only through randomized trials will better guides to better treatment be established.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280813      PMCID: PMC2625629     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  44 in total

1.  Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen.

Authors:  C Huggins; W W Scott
Journal:  Ann Surg       Date:  1945-12       Impact factor: 12.969

2.  Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases.

Authors:  R M NESBIT; W C BAUM
Journal:  J Am Med Assoc       Date:  1950-08-12

3.  Cancer in advancing age.

Authors:  R B Malkin; T Strax; J C Wright
Journal:  J Natl Med Assoc       Date:  1969-05       Impact factor: 1.798

Review 4.  Response criteria in urologic malignancies.

Authors:  F M Torti
Journal:  Recent Results Cancer Res       Date:  1983

Review 5.  The chemotherapy of prostatic adenocarcinoma.

Authors:  F M Torti; S K Carter
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

6.  The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.

Authors:  W W Scott; R P Gibbons; D E Johnson; G R Prout; J D Schmidt; J Saroff; G P Murphy
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

7.  Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.

Authors:  H B Muss; V Howard; F Richards; D R White; D V Jackson; M R Cooper; J J Stuart; M I Resnick; R Brodkin; C L Spurr
Journal:  Cancer       Date:  1981-04-15       Impact factor: 6.860

8.  Treatment of estrogen-resistant stage D carcinoma of prostate with cis diamminedichloroplatinum.

Authors:  C E Merrin; S Beckley
Journal:  Urology       Date:  1979-03       Impact factor: 2.649

9.  Experience with flutamide in previously untreated patients with advanced prostatic cancer.

Authors:  P C Sogani; W F Whitmore
Journal:  J Urol       Date:  1979-11       Impact factor: 7.450

10.  A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.

Authors:  R V Smalley; A A Bartolucci; G Hemstreet; M Hester
Journal:  J Urol       Date:  1981-02       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.